Obesity

Pfizer's GLP-1-RA Program: Obesity and Type 2 Diabetes Update

Pfizer’s GLP-1-RA Program: Obesity and Type 2 Diabetes Update

Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus Pfizer Inc. has announced its decision to continue to progress one oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate toward further clinical development for the potential treatment of adults with obesity and Type 2 diabetes mellitus (T2DM). Moving […]

Pfizer’s GLP-1-RA Program: Obesity and Type 2 Diabetes Update Read More »

Obesity accelerates loss of COVID-19 vaccination immunity: study

Obesity accelerates loss of COVID-19 vaccination immunity: study

The protection offered by COVID-19 vaccination declines more rapidly in people with severe obesity than in those with normal weight, scientists at the University of Cambridge and Edinburgh University have found. The study suggests that people with obesity are likely to need more frequent booster doses to maintain their immunity.  Clinical trials have shown that

Obesity accelerates loss of COVID-19 vaccination immunity: study Read More »